Richard has more than 25 years experience in pharmaceutical research and development, and has been involved in the development of a large number of successful, marketed pharmaceutical products.
He has held senior management positions within preclinical safety (a vital precursor to human trials), including Head of Toxicology at pharmaceutical giant Wellcome plc and International Head of Toxicology and Preclinical Outsourcing for GlaxoWellcome (later GlaxoSmithKline). He has been responsible for evaluating the preclinical safety of more than 100 new chemical entities, ranging from anti-infectives and anti-parasitics to cancer compounds and vaccines. Richard currently advises UK and Australian companies on toxicology and preclinical discovery and development.
Richard consults to the company on the preclinical safety aspects of developing products. |